PMID

Data

Article Title

Organization

Dihydropyrrolo[2,3-d]pyrimidines: Selective Toll-Like Receptor 9 Antagonists from Scaffold Morphing Efforts.

Sumitomo Dainippon Pharma

Small molecule modulators of toll-like receptors.

Schering-Plough Research Institute

Identification of 2-Pyridinylindole-Based Dual Antagonists of Toll-like Receptors 7 and 8 (TLR7/8).

Biocon Bristol Myers Squibb Research Center (Bbrc)

Development, Optimization, and In Vivo Validation of New Imidazopyridine Chemotypes as Dual TLR7/TLR9 Antagonists through Activity-Directed Sequential Incorporation of Relevant Structural Subunits.

Csir-Indian Institute of Chemical Biology

Small molecule approaches to treat autoimmune and inflammatory diseases (Part II): Nucleic acid sensing antagonists and inhibitors.

Roche Innovation Center Shanghai

Structure-Based Optimization of a Fragment-like TLR8 Binding Screening Hit to an

Novartis Institutes For Biomedical Research

Spiro(isobenzofuranazetidine) Compounds for Treating Autoimmune Diseases.

Smith, Gambrell & Russell

Systematic Optimization of Potent and Orally Bioavailable Purine Scaffold as a Dual Inhibitor of Toll-Like Receptors 7 and 9.

Csir-Indian Institute of Chemical Biology

Novel Triazatricycle Compounds for Treating Autoimmune Diseases.

Smith, Gambrell & Russell

Novel Carbazoles for Treating Inflammatory and Autoimmune Diseases.

Smith, Gambrell & Russell

Identification of a Human Toll-Like Receptor (TLR) 8-Specific Agonist and a Functional Pan-TLR Inhibitor in 2-Aminoimidazoles.

University of Kansas

Discovery of potent, orally bioavailable in vivo efficacious antagonists of the TLR7/8 pathway.

Genomics Institute of The Novartis Research Foundation

Novel Hexahydro-1

Smith, Gambrell & Russell

Discovery of Potent and Orally Bioavailable Small Molecule Antagonists of Toll-like Receptors 7/8/9 (TLR7/8/9).

Princ

Target-Based Identification and Optimization of 5-Indazol-5-yl Pyridones as Toll-like Receptor 7 and 8 Antagonists Using a Biochemical TLR8 Antagonist Competition Assay.

Genomics Institute of The Novartis Research Foundation

Discovery of a First-in-Class Receptor Interacting Protein 2 (RIP2) Kinase Specific Clinical Candidate, 2-((4-(Benzo[

Glaxosmithkline

Activity-guided development of potent and selective toll-like receptor 9 antagonists.

Csir-Indian Institute of Chemical Biology

Design and development of benzoxazole derivatives with toll-like receptor 9 antagonism.

Csir-Indian Institute of Chemical Biology

Discovery of Small Molecules as Multi-Toll-like Receptor Agonists with Proinflammatory and Anticancer Activities.

University of Colorado Boulder

Chemotype-selective modes of action of ¿-opioid receptor agonists.

University of North Carolina

Thermodynamics of binding of structurally similar ligands to histone deacetylase 8 sheds light on challenges in the rational design of potent and isozyme-selective inhibitors of the enzyme.

North Dakota State University

Isofagomine- and 2,5-anhydro-2,5-imino-D-glucitol-based glucocerebrosidase pharmacological chaperones for Gaucher disease intervention.

The Scripps Research Institute

Methylxanthine drugs are chitinase inhibitors: investigation of inhibition and binding modes.

University of Dundee